Spray-Dried Biologics Global Market Report 2025

The spray-dried biologics market size has grown rapidly in recent years. It will grow from $1.66 billion in 2024 to $1.86 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period resulted from increasing outsourcing of biomanufacturing activities, rising demand for stable high-value biologic formulations, growing focus on extending the shelf life of complex therapeutics, a surge in global biologics production volumes, expansion of contract development and manufacturing activities, and increasing commercialization of temperature-sensitive biologic drugs.

The spray-dried biologics market size is expected to see rapid growth in the next few years. It will grow to $2.87 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period will be driven by growing demand for long-term room-temperature-stable biologics, rising investment in large-scale biologics manufacturing worldwide, increasing adoption of outsourced formulation and processing services, a surge in the development of novel biologic drug classes that require robust stabilization, expansion of biologics pipelines across emerging markets, and increasing emphasis on supply-chain efficiency and reduced cold-chain dependence. Major trends in the forecast period include technological advancements in particle engineering platforms, progress in continuous spray-drying systems for biologics, innovations in high-precision droplet and drying control technologies, developments in hybrid drying and encapsulation methods, research and development in excipient systems designed for biologic stabilization, and innovations in integrated fill-finish and dry-powder handling solutions.

The growing demand for biopharmaceuticals is expected to drive the expansion of the spray-dried biologics market in the coming years. Biopharmaceuticals are therapeutic products derived from biological sources, including living cells, proteins, and other biomolecules. This demand is increasing due to the global rise in chronic and complex health conditions, which has created a need for therapies that provide higher specificity, improved efficacy, and fewer systemic side effects. The spray-dried biologics sector is seeing heightened interest as the rapid growth of biopharmaceuticals encourages companies to adopt scalable formulation technologies that enhance stability, shelf life, and delivery efficiency. For example, in February 2025, the World Health Organization (WHO), a Switzerland-based international public health agency, reported that the 2023 WHO Essential Medicines List included 81 biologic therapies, representing more than 15% of all essential medicines. Consequently, the rising demand for biopharmaceuticals is driving the growth of the spray-dried biologics market.

Key players in the spray-dried biologics market are focusing on integrating technological innovations such as drum dosing technology to improve dose accuracy, powder handling efficiency, and reliable large-scale capsule filling. Drum dosing technology is an advanced powder-filling method that uses a rotating drum with precision-engineered dosing cavities and vacuum-assisted transfer to accurately meter and deposit dry powders into capsules. This approach enables consistent low-dose filling, better flow management of spray-dried powders, and high-throughput scalability. For instance, in February 2024, Catalent Inc., a US-based contract development and manufacturing organization (CDMO), upgraded its inhalation manufacturing facility in the US with potent capsule-filling capabilities using drum-based dosing systems and in-line advanced mass verification. This upgraded platform supports precise filling of engineered and spray-dried powders, featuring real-time dose validation and controlled low-humidity processing, thereby enhancing manufacturing efficiency, product consistency, and readiness for commercial-scale production of spray-dried biologic dry-powder inhalation therapies.

In May 2023, Hovione, a Portugal-based integrated CDMO specializing in spray drying and particle engineering, partnered with H&T Presspart to advance high-efficiency device technology for dry powder inhalation delivery. This collaboration aims to strengthen Hovione’s capabilities in engineered spray-dried and high-dose inhalation formulations by leveraging Presspart’s Sunriser capsule-based dry powder inhaler platform to improve the performance and commercial readiness of inhalation therapies. H&T Presspart, based in Germany, specializes in drug-delivery devices and inhalation technology.

Major companies operating in the spray-dried biologics market are Thermo Fisher Scientific Inc., Evonik Industries AG, Lonza Group AG, GEA Group, Fareva Group, Almac Group Limited, Seqens Group, Fabbrica Italiana Sintetici S.p.A., CordenPharma International, Hovione FarmaCiencia SA, Veranova Inc., Pace Analytical Services LLC, Olon S.p.A., Nova Laboratories Ltd, Leukocare AG, Micro Sphere SA, Seran Bioscience LLC, CritiTech Particle Engineering Solutions LLC, Xedev BV, BÜCHI Labortechnik AG.

North America was the largest region in the spray-dried biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spray-dried biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the spray-dried biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The spray-dried biologics market research report is one of a series of new reports that provides spray-dried biologics market statistics, including the spray-dried biologics industry global market size, regional shares, competitors with the spray-dried biologics market share, detailed spray-dried biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the spray-dried biologics industry. This spray-dried biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Spray-dried biologics are biologic drugs that have been converted from a liquid formulation into a dry powder through a rapid drying method. In this process, the liquid is sprayed into heated air, allowing moisture to evaporate quickly while preserving the integrity of sensitive components such as proteins, vaccines, or enzymes. The resulting dry powder provides benefits such as improved stability, easier handling, and suitability for various delivery routes.

The main product types of spray-dried biologics include monoclonal antibodies, vaccines, enzymes, hormones, and others. Monoclonal antibodies are laboratory-developed molecules that are engineered to identify and bind to a specific target antigen with high accuracy. The different routes of administration include oral, inhalation or pulmonary, injectable, and topical, and these products serve end users such as hospitals, research institutes, pharmaceutical and biotechnology companies, and others.

The spray-dried biologics market consists of sales of peptide therapeutics, deoxyribonucleic acid vaccines, ribonucleic acid vaccines, nanobodies, antibody-drug conjugates, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.